--Actinium Pharmaceuticals, Inc., a pioneer in the development of targeted radiotherapies, today announced preclinical results with ATNM-400 in prostate cancer models presented at the American ...
New preclinical findings demonstrate ATNM-400 overcomes resistance to the EGFR inhibitor osimertinib in EGFR-mutated NSCLC, addressing a major unmet clinical need NEW YORK, Oct. 13, 2025 /PRNewswire/ ...
- ATNM-400 targets a highly differentiated, non-PSMA antigen associated with the development and progression of prostate cancer, exhibiting potent therapeutic activity independent of PSMA expression ...
Actinium Pharmaceuticals Inc. (ATNM) on Monday reported a loss of $5.9 million in its fourth quarter.
Actinium Pharmaceuticals is a late-stage biopharmaceutical company focused on developing radiotherapies for AML patients. The company's leading product candidate, Iomab-B, has shown promising results ...
- 99.8% tumor growth inhibition achieved with a single dose of ATNM-400 in preclinical prostate cancer models - ATNM-400 accumulated in tumors for up to 144 hours and showed minimal uptake in healthy ...
Betting Big On The Explosive Global Cancer Radiotherapy Boom. November 17, 2025- (Investorideas Newswire), a go-to investing platform covering biotech and pharma stocks issues a snapshot looking at ...
Presentation to include new data in triple-negative disease, a breast cancer subtype with poor outcomes and limited viable treatment options ATNM-400 overcomes HER2 therapy resistance and represents a ...
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results